Considering aesthetic surgery? You need to do your research and become an informed consumer.

Home

Search

Article Archive

Resources / Links

Aesthetic Surgery Books

Skin Care Store

Free Newsletter

Second in a Series of New Endotine Product Offerings

(press release from Coapt Systems, Inc.)

PALO ALTO, Calif., March 16 -- Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has initiated commercialization of the ENDOTINE Midface ST 4.5 for midface suspension surgery. The ENDOTINE Midface received FDA clearance in October 2003 and has since undergone and completed an IRB-approved clinical evaluation.

"This product is the second in a series of products that we plan to introduce over the next twelve months that will enable us to build an enduring franchise in the plastic surgery market," said John Kraczkowsky, Senior Vice President, Sales and Marketing. "We're especially excited about the ENDOTINE Midface product, because it addresses the challenge that so many of our customers have expressed regarding the shortcomings of current midface suspension techniques."

There are nearly 400,000 facelifts performed worldwide each year, many of which involve a midface lift. The midface lift is one of the most rapidly growing segments of the facelift market as baby boomers seek a less invasive, more subtle change in their appearance.

"Many of my patients in the 35 to 50 age group are not looking for a radical makeover, but rather a more understated rejuvenation that brings them back seven to ten years," said Dr. N.D. Moscoe, a board certified plastic and reconstructive surgeon from Austin, Texas. "Because this implant is designed to offer enhanced cheek volume while reducing the complexity of the procedure, I believe that many surgeons will begin to proactively market this as a major part of their facial practice."

According to Dr. Daniel Jacobs, company founder and practicing plastic surgeon, "the ENDOTINE Midface provides a logical alternative for surgeons frustrated with the limitations of suture based midface suspension techniques. These are cumbersome techniques that can be technically very challenging, oftentimes prolonging OR time and leading to sub-optimal outcomes."

By eliminating the need for fixation sutures, which are the most commonly used devices for midface suspension, surgeons find the ENDOTINE Midface much simpler and easier to use. And its absorbable tines capture and elevate the cheek, holding it in position until the soft tissues re-adhere to the cheek bone. The device then gradually absorbs until it is completely gone.

The ENDOTINE Midface is now available throughout the U.S. Coapt plans to introduce the product into many key international markets by the end of the year.

About Coapt Systems

Coapt Systems develops, manufactures and markets a range of bio-absorbable implants for use in soft tissue fixation based upon its patented MultiPoint Technology (MPT(TM)) platform. Founded in 2000, the company is committed to innovation in soft tissue surgery and the development of devices that enable optimal aesthetic outcomes. Coapt's first product, the ENDOTINE Forehead, has received FDA approval for browplasty and is available for sale in the U.S. and multiple international markets. The ENDOTINE Midface has received FDA approval for midface suspension and is available for sale in the U.S. Additional facial products under development will address the eyelid (blepharoplasty), chin (mentoplasty) and neck (platysmaplasty) markets. The company is also developing products for hand tendon and scapholunate repair. Located in Palo Alto, California, Coapt Systems, Inc. is a privately held company with 40 employees.

Visit our website: www.coaptsystems.com

For further information contact: John Kraczkowsky, Senior Vice President, Sales and Marketing at 650-461-7660.

Knowledge is Power. Information is How You Get It!

PROACTIV SOLUTION ACNE TREATMENT

HYLEXIN

AlphaDerma CE